Douglas Sborov Selected Research

belantamab mafodotin

12/2023	Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
1/2022	Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma.
11/2021	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
1/2021	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
12/2020	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
12/2020	Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
1/2020	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas Sborov Research Topics

Disease

14	Multiple Myeloma 01/2024 - 01/2020
2	Disease Progression 11/2021 - 01/2020
2	Neoplasms (Cancer) 10/2021 - 04/2015
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2024
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2023
1	Amyloidosis 01/2023
1	Leukemia 06/2022
1	Immunoglobulin Light-chain Amyloidosis 01/2022
1	Lymphoma (Lymphomas) 07/2021
1	Infections 03/2021
1	Death (Near-Death Experience) 03/2021
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Sarcoma (Soft Tissue Sarcoma) 04/2015

Drug/Important Bio-Agent (IBA)

7	belantamab mafodotinIBA 12/2023 - 01/2020
3	isatuximabIBA 12/2021 - 01/2020
3	Monoclonal AntibodiesIBA 12/2021 - 01/2020
3	Immunoconjugates (Immunoconjugate)IBA 12/2020 - 01/2020
2	Proteasome InhibitorsIBA 11/2021 - 01/2020
2	Immunomodulating AgentsIBA 11/2021 - 01/2020
2	daratumumabIBA 07/2021 - 01/2021
1	Adenosine Monophosphate (AMP)IBA 01/2024
1	Etoposide (VP 16)FDA LinkGeneric 10/2023
1	Amyloid (Amyloid Fibrils)IBA 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	Dexamethasone (Maxidex)FDA LinkGeneric 12/2021
1	pomalidomideIBA 12/2021
1	Chimeric Antigen ReceptorsIBA 10/2021
1	Vorinostat FDA Link 01/2020
1	Lenalidomide (CC 5013)FDA Link 01/2020
1	B-Cell Maturation AntigenIBA 01/2020

Therapy/Procedure

9	Therapeutics 06/2023 - 04/2015
2	Autologous Transplantation 01/2023 - 01/2020
1	Hematopoietic Stem Cell Transplantation 01/2023
1	Drug Therapy (Chemotherapy) 06/2022
1	Blood Transfusion (Blood Transfusions) 03/2021
1	Palliative Care (Palliative Therapy) 03/2021
1	Intravenous Infusions 01/2020
1	Stem Cell Transplantation 01/2020